Shares of Myomo, Inc. (NASDAQ:MYO) have been assigned an average broker rating score of 1.00 (Strong Buy) from the one brokers that cover the company, Zacks Investment Research reports. One equities research analyst has rated the stock with a strong buy rating.
Analysts have set a 12 month consensus price target of $3.00 for the company and are expecting that the company will post ($0.16) EPS for the current quarter, according to Zacks. Zacks has also given Myomo an industry rank of 148 out of 256 based on the ratings given to related companies.
Separately, Roth Capital reaffirmed a “buy” rating on shares of Myomo in a research note on Tuesday, February 5th.
Myomo stock traded down $0.10 during trading hours on Friday, hitting $0.93. 301,600 shares of the stock were exchanged, compared to its average volume of 99,744. Myomo has a 12 month low of $0.90 and a 12 month high of $3.52.
Myomo (NASDAQ:MYO) last issued its quarterly earnings data on Thursday, March 7th. The company reported ($0.22) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.23) by $0.01. The firm had revenue of $0.89 million for the quarter, compared to the consensus estimate of $0.70 million.
Myomo Company Profile
Myomo, Inc, a commercial stage medical robotics company, designs, develops, and produces myoelectric braces or orthotics for people suffering with neuromuscular disorders in the United States. It offers MyoPro, a powered upper limb orthosis that supports the arm, as well as restores function to the weakened or paralyzed arms of patients suffering from CVA stroke, brachial plexus injury, traumatic brain injury, spinal cord injury, ALS, or other neuromuscular disease or injury.
Featured Article: What is an overbought condition?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Myomo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myomo and related companies with MarketBeat.com's FREE daily email newsletter.